Document is current
Any future updates will be listed below
-
Authors
Doss, Manoj K. https://orcid.org/0000-0003-2939-2522
DeMarco, AnnaMarie https://orcid.org/0000-0002-4359-5927
Dunsmoor, Joseph E. https://orcid.org/0000-0002-5448-6873
Cisler, Josh M. https://orcid.org/0000-0001-8257-7716
Fonzo, Gregory A. https://orcid.org/0000-0002-0213-1034
Nemeroff, Charles B. https://orcid.org/0000-0001-7867-1160
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R01MH122387, R61MH132722, R33MH108753, R01MH119132, K23MH114023, R01MH117293, R01MH122387, R01MH125886, R01MH129694)
National Science Foundation (1844792)
United States - Israel Binational Science Foundation (AWD00003047)
National Institute on Alcohol Abuse and Alcoholism (R01AA030740, R01AA029090, R01AA030038)
Texas Child Mental Health Care Consortium (TCMHCC)
- License Information
-
More Information
Article History
Accepted: 4 October 2024
First Online: 26 October 2024
Declarations
:
: JED receives research support from the National Institutes of Health (NIH), National Science Foundation (NSF), and US-Israel Binational Science Foundation. JMC receives research support from NIH and Texas Child Mental Health Care Consortium. GAF receives research support from the Brain and Behavior Research Foundation, NIH (with grant numbers R61MH132722, R33MH108753, R01MH119132, R01AA030740, K23MH114023, TCMHCC, R01MH117293, R01AA029090, R01MH122387, R01MH125886, R01AA030038, R01MH129694 ), and the One Mind–Baszucki Brain Research Fund. CBN receives research support from NIH and Texas Child Mental Health Care Consortium. These funding sources had no role in the writing of this manuscript other than supporting salaries.
: Manoj K. Doss is an advisor to VCENNA. Gregory A. Fonzo has served as a consultant for SynapseBio AI, and is a stockholder in Alto Neuroscience. Charles B. Nemeroff has served as a consultant for AbbVie, ANeuroTech (division of Anima BV), BioXcel Therapeutics, Clexio, EMA Wellness, EmbarkNeuro, Engrail Therapeutics, Intra-Cellular Therapies, GoodCap Pharmaceuticals, Magstim, Ninnion Therapeutics, Pasithea Therapeutics, Sage, Senseye, Signant Health, Silo Pharma, SynapseBio, and Relmada Therapeutics; has served on scientific advisory boards for ANeuroTech, the Anxiety and Depression Association of America (ADAA), the Brain and Behavior Research Foundation, Heading Health, the Laureate Institute for Brain Research, Pasithea Therapeutics, Sage, Signant Health, and Skyland Trail, and on the Boards of Directors for ADAA, Gratitude America, and Lucy Scientific Discovery; is a stockholder in Corcept Therapeutics, EMA Wellness, Galen Mental Health, Relmada Therapeutics; and is named on patents related to psychiatric treatment. None of these groups had any role in the writing of this manuscript. AnnaMarie DeMarco, Joseph E. Dunsmoor, and Josh M. Cisler have no conflicts of interest to declare that may be relevant to the contents of this article.
: Not applicable.
: Not applicable.
: The journal has our consent to publish.
: Not applicable.
: Not applicable.
: MKD conceived of the ideas behind this manuscript and wrote the original manuscript. AdM, JED, JMC, GAF, and CBN conceived of the ideas behind this manuscript and edited the manuscript. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.
